| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Sorafenib in advanced hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
54.30
|
|
2
|
Hepatocellular carcinoma.
|
Lancet
|
2003
|
22.54
|
|
3
|
Hepatocellular carcinoma.
|
Lancet
|
2012
|
18.09
|
|
4
|
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
|
Lancet
|
2002
|
12.16
|
|
5
|
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.
|
Hepatology
|
2003
|
11.55
|
|
6
|
Design and endpoints of clinical trials in hepatocellular carcinoma.
|
J Natl Cancer Inst
|
2008
|
11.27
|
|
7
|
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
9.20
|
|
8
|
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.
|
Hepatology
|
2008
|
6.75
|
|
9
|
Molecular targeted therapies in hepatocellular carcinoma.
|
Hepatology
|
2008
|
6.16
|
|
10
|
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.
|
Lancet Oncol
|
2008
|
5.93
|
|
11
|
Current strategy for staging and treatment: the BCLC update and future prospects.
|
Semin Liver Dis
|
2010
|
5.85
|
|
12
|
Novel advancements in the management of hepatocellular carcinoma in 2008.
|
J Hepatol
|
2008
|
5.24
|
|
13
|
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
|
J Hepatol
|
2006
|
5.17
|
|
14
|
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
|
Cancer Res
|
2008
|
4.35
|
|
15
|
Pivotal role of mTOR signaling in hepatocellular carcinoma.
|
Gastroenterology
|
2008
|
4.03
|
|
16
|
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.
|
Hepatology
|
2007
|
3.85
|
|
17
|
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
|
J Clin Oncol
|
2013
|
3.71
|
|
18
|
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis.
|
Hepatology
|
2015
|
3.63
|
|
19
|
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
|
Clin Cancer Res
|
2012
|
3.39
|
|
20
|
Management of HCC.
|
J Hepatol
|
2012
|
3.03
|
|
21
|
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma.
|
Radiology
|
2013
|
2.76
|
|
22
|
Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
|
Gut
|
2012
|
2.70
|
|
23
|
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.
|
Gastroenterology
|
2011
|
2.66
|
|
24
|
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
|
Liver Transpl
|
2004
|
2.65
|
|
25
|
Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound.
|
Hepatology
|
2010
|
2.61
|
|
26
|
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.
|
Hepatology
|
2004
|
2.54
|
|
27
|
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
|
J Hepatol
|
2012
|
2.53
|
|
28
|
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
|
J Hepatol
|
2009
|
2.42
|
|
29
|
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
|
Gastroenterology
|
2013
|
2.42
|
|
30
|
Gene-expression signature of vascular invasion in hepatocellular carcinoma.
|
J Hepatol
|
2011
|
2.39
|
|
31
|
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
|
Cancer
|
2009
|
2.38
|
|
32
|
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
|
Gastroenterology
|
2006
|
2.32
|
|
33
|
Angiogenesis in liver disease.
|
J Hepatol
|
2008
|
2.31
|
|
34
|
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma.
|
Hepatology
|
2004
|
2.29
|
|
35
|
Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.
|
Hepatology
|
2009
|
2.10
|
|
36
|
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.
|
J Hepatol
|
2006
|
1.98
|
|
37
|
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.
|
Hepatology
|
2003
|
1.85
|
|
38
|
Chemoembolization for intermediate HCC: is there proof of survival benefit?
|
J Hepatol
|
2011
|
1.84
|
|
39
|
Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers.
|
Hepatology
|
2003
|
1.80
|
|
40
|
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
|
Gastroenterology
|
2009
|
1.79
|
|
41
|
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.
|
Gastroenterology
|
2011
|
1.77
|
|
42
|
Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star.
|
Gastroenterology
|
2009
|
1.70
|
|
43
|
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
|
J Hepatol
|
2010
|
1.66
|
|
44
|
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.
|
Liver Transpl
|
2004
|
1.65
|
|
45
|
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.
|
Hepatology
|
2010
|
1.64
|
|
46
|
Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis.
|
Virol J
|
2006
|
1.58
|
|
47
|
Hepatocellular carcinoma (HCC): a global perspective.
|
J Clin Gastroenterol
|
2010
|
1.49
|
|
48
|
The search for an effective partner for sorafenib: the failure of doxorubicin.
|
Gastroenterology
|
2011
|
1.45
|
|
49
|
Treatment of hepatocellular carcinoma.
|
Crit Rev Oncol Hematol
|
2006
|
1.45
|
|
50
|
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
|
Clin Cancer Res
|
2012
|
1.44
|
|
51
|
Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma.
|
Cancer Res
|
2003
|
1.40
|
|
52
|
Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI.
|
J Hepatol
|
2012
|
1.37
|
|
53
|
Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations.
|
Hepatology
|
2012
|
1.37
|
|
54
|
LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions.
|
Hepatology
|
2014
|
1.31
|
|
55
|
Treatment of hepatocellular carcinoma: is there an optimal strategy?
|
Cancer Treat Rev
|
2003
|
1.25
|
|
56
|
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
|
Hepatology
|
2013
|
1.19
|
|
57
|
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.
|
BMC Cancer
|
2010
|
1.15
|
|
58
|
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.
|
Clin Cancer Res
|
2013
|
1.12
|
|
59
|
HCC surveillance: who is the target population?
|
Hepatology
|
2003
|
1.12
|
|
60
|
Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice.
|
Hepatology
|
2015
|
1.09
|
|
61
|
Biomarkers for early diagnosis of hepatocellular carcinoma.
|
Lancet Oncol
|
2012
|
1.02
|
|
62
|
Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.
|
J Hepatol
|
2011
|
1.01
|
|
63
|
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
|
J Hepatol
|
2012
|
1.01
|
|
64
|
Prognosis of hepatocellular carcinoma.
|
Hepatogastroenterology
|
2002
|
1.01
|
|
65
|
Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision.
|
Liver Transpl
|
2003
|
0.98
|
|
66
|
Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma.
|
J Oncol Pract
|
2011
|
0.98
|
|
67
|
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
|
J Hepatol
|
2013
|
0.96
|
|
68
|
Prognostic prediction in patients with hepatocellular carcinoma.
|
Semin Liver Dis
|
2005
|
0.94
|
|
69
|
Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study.
|
Hepatogastroenterology
|
2004
|
0.92
|
|
70
|
Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography.
|
Liver Transpl
|
2004
|
0.91
|
|
71
|
Treatment of early hepatocellular carcinoma: Towards personalized therapy.
|
Dig Liver Dis
|
2010
|
0.91
|
|
72
|
Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line.
|
Clin Cancer Res
|
2004
|
0.91
|
|
73
|
Treatment strategies for hepatocellular carcinoma in cirrhosis.
|
J Gastrointest Surg
|
2003
|
0.87
|
|
74
|
Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines.
|
Ann Saudi Med
|
2012
|
0.87
|
|
75
|
p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma.
|
J Hepatol
|
2003
|
0.86
|
|
76
|
Treatment of hepatocellular carcinoma.
|
Dig Dis
|
2014
|
0.85
|
|
77
|
New drugs for the treatment of hepatocellular carcinoma.
|
Liver Int
|
2009
|
0.85
|
|
78
|
A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma.
|
J Mol Med (Berl)
|
2013
|
0.84
|
|
79
|
Screening for liver cancer: the rush to judgment.
|
Ann Intern Med
|
2012
|
0.84
|
|
80
|
[Diagnosis and treatment of hepatocellular carcinoma].
|
Med Clin (Barc)
|
2009
|
0.84
|
|
81
|
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.
|
J Clin Oncol
|
2009
|
0.83
|
|
82
|
Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography.
|
Dig Dis Sci
|
2005
|
0.83
|
|
83
|
Hepatocellular carcinoma in the setting of liver transplantation.
|
Liver Transpl
|
2006
|
0.82
|
|
84
|
Ablation for hepatocellular carcinoma: Is there need to have a winning technique?
|
J Hepatol
|
2010
|
0.82
|
|
85
|
Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma.
|
Eur J Gastroenterol Hepatol
|
2010
|
0.82
|
|
86
|
Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care.
|
Hepatology
|
2008
|
0.82
|
|
87
|
Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there.
|
Semin Liver Dis
|
2006
|
0.81
|
|
88
|
Antiangiogenic therapy: not just for cancer anymore?
|
Hepatology
|
2009
|
0.81
|
|
89
|
Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience.
|
HPB (Oxford)
|
2014
|
0.81
|
|
90
|
Liver transplantation in hepatocellular carcinoma.
|
Transpl Int
|
2005
|
0.81
|
|
91
|
East meets the West--portal pressure predicts outcome of surgical resection for hepatocellular carcinoma.
|
Nat Clin Pract Gastroenterol Hepatol
|
2008
|
0.81
|
|
92
|
Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models.
|
Hepatology
|
2010
|
0.81
|
|
93
|
Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients.
|
J Hepatol
|
2005
|
0.81
|
|
94
|
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
|
Med Clin (Barc)
|
2009
|
0.81
|
|
95
|
Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.
|
Radiology
|
2015
|
0.80
|
|
96
|
Diagnosis of Small HCC.
|
Gastroenterology
|
2005
|
0.80
|
|
97
|
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
|
J Hepatol
|
2012
|
0.79
|
|
98
|
Diagnosis and staging of hepatocellular carcinoma prior to transplantation: expertise or failure.
|
Liver Transpl
|
2006
|
0.79
|
|
99
|
Liver cancer: An evolving challenge reaching research maturity.
|
Hepatology
|
2008
|
0.79
|
|
100
|
Selection of candidates with HCC for transplantation in the MELD era.
|
Liver Transpl
|
2004
|
0.79
|
|
101
|
Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation.
|
J Clin Ultrasound
|
2003
|
0.79
|
|
102
|
Transarterial chemoembolization for patients with hepatocellular carcinoma.
|
Hepatol Res
|
2007
|
0.78
|
|
103
|
Treating hepatitis C in patients with cirrhosis: the effort is worth it.
|
J Hepatol
|
2010
|
0.78
|
|
104
|
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
|
J Hepatol
|
2010
|
0.78
|
|
105
|
Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization.
|
Radiology
|
2004
|
0.77
|
|
106
|
Sorafenib for hepatocellular carcinoma: global validation.
|
Gastroenterology
|
2009
|
0.77
|
|
107
|
Diagnosis of early hepatocellular carcinoma: ideal goal, but not yet there.
|
Gastroenterology
|
2010
|
0.77
|
|
108
|
Expected developments in hepatology.
|
Best Pract Res Clin Gastroenterol
|
2002
|
0.77
|
|
109
|
To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer?
|
Gastroenterology
|
2009
|
0.76
|
|
110
|
The size of the problem: clinical algorithms.
|
Dig Dis
|
2013
|
0.76
|
|
111
|
Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma.
|
Ann Surg
|
2015
|
0.75
|
|
112
|
Treatment of hepatocellular carcinoma with radioembolization: gathering assumptions for trial design.
|
J Vasc Interv Radiol
|
2013
|
0.75
|
|
113
|
Applicability of adult-to-adult living donor liver transplantation.
|
J Hepatol
|
2005
|
0.75
|
|
114
|
MicroRNA analysis for outcome prediction in hepatitis B virus-related liver cancer.
|
Gastroenterology
|
2010
|
0.75
|
|
115
|
Failure of interferon to prevent disease progression and liver cancer in hepatitis C virus infection: proof of absence or absence of proof?
|
Gastroenterology
|
2009
|
0.75
|
|
116
|
Response.
|
Radiology
|
2013
|
0.75
|
|
117
|
Sunitinib and the benefits of a negative study.
|
Lancet Oncol
|
2009
|
0.75
|
|
118
|
Systemic Treatment: Expecting Further Success.
|
Dig Dis
|
2015
|
0.75
|
|
119
|
Liver cancer: still a long way to go.
|
Hepatology
|
2011
|
0.75
|
|
120
|
Treatment of Hepatocellular Carcinoma.
|
Dig Dis
|
2016
|
0.75
|
|
121
|
Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
|
J Hepatobiliary Pancreat Sci
|
2009
|
0.75
|
|
122
|
If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?
|
Liver Int
|
2013
|
0.75
|
|
123
|
[Treatment of advanced hepatocellular carcinoma].
|
Gastroenterol Hepatol
|
2010
|
0.75
|